SCHEMBL20927336

SCHEMBL20927336

C=C(Nc1ccc(Oc2ccnc3cc(OC)c(C(=O)O)cc23)cc1Cl)NC1CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 12/20 0.72
▸ KDR P35968 8/20 0.72
▸ FGFR1 P11362 5/20 0.72
▸ PDGFRA P16234 5/20 0.72
▸ PDGFRB P09619 4/20 0.72
▸ AURKB Q96GD4 4/20 0.72
▸ RET P07949 3/20 0.72
▸ KIT P10721 3/20 0.72
▸ FLT1 P17948 3/20 0.72
▸ FLT4 P35916 3/20 0.72
▸ FGFR2 P21802 3/20 0.72
▸ FGFR3 P22607 3/20 0.72
▸ ABL1 P00519 3/20 0.72
▸ RIPK2 O43353 2/20 0.72
▸ STK10 O94804 2/20 0.72
▸ BCR P11274 2/20 0.72
▸ SLC6A3 Q01959 2/20 0.72
▸ DDR1 Q08345 2/20 0.72
▸ MAP4K2 Q12851 2/20 0.72
▸ PTK6 Q13882 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20927411 0.94 FGFR4 (0.73) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL20927261 0.93 FGFR4 (0.85) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL1894427 0.92 FGFR4 (0.86) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL30083661 0.92 FGFR4 (0.86) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL20927307 0.91 FGFR4 (0.69) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL19957112 0.90 FGFR4 (0.72) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL20927341 0.90 KDR (0.79) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL20927342 0.87 FGFR4 (0.76) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL1248140 0.85 FGFR4 (0.87) FGFR4KDRFGFR1PDGFRAPDGFRB
SCHEMBL20927323 0.85 FGFR4 (0.73) FGFR4KDRFGFR1PDGFRAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 — — US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 FGFR4 146/4885KDR 150/4885FGFR1 44/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 FGFR4 146/4885KDR 150/4885FGFR1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback